Literature DB >> 1720039

Effect of c-kit ligand on in vitro human megakaryocytopoiesis.

R A Briddell1, E Bruno, R J Cooper, J E Brandt, R Hoffman.   

Abstract

An evaluation of the effects of a recombinant, soluble form of the c-kit ligand alone and in combination with either granulocyte-macrophage colony-stimulating factor (GM-CSF) or interleukin-3 (IL-3) on the regulation of human megakaryocytopoiesis was performed using a serum-depleted clonal assay system and a long-term bone marrow culture system. The effects of the c-kit ligand on the primitive megakaryocyte (MK) progenitor cell, the burst-forming unit-megakaryocyte (BFU-MK), and the more differentiated colony-forming unit-megakaryocyte (CFU-MK) were determined. The c-kit ligand alone had no megakaryocyte colony-stimulating activity (MK-CSA) but was capable of augmenting the MK-CSA of both GM-CSF and IL-3. The range of synergistic interactions of c-kit ligand varied with the class of MK progenitor cell assayed. In the case of the BFU-MK, the c-kit ligand synergistically augmented the numbers of colonies formed in the presence of IL-3, but not GM-CSF, but increased the size of BFU-MK-derived colonies cloned in the presence of both of these cytokines. However, at the level of the CFU-MK, c-kit ligand synergized with both GM-CSF and IL-3 by increasing both colony numbers and size. Although the c-kit ligand alone exhibited limited potential in sustaining long-term megakaryocytopoiesis in vitro, it synergistically augmented the ability of IL-3, but not GM-CSF, to promote long-term megakaryocytopoiesis. These data indicate that multiple cytokines are necessary to optimally stimulate the proliferation of both classes of MK progenitor cells and that the c-kit ligand plays a significant role in this process by amplifying the MK-CSA of both GM-CSF and IL-3.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1720039

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

1.  Cytokine production by a megakaryocytic cell line.

Authors:  B Sandrock; K M Hudson; D E Williams; M A Lieberman
Journal:  In Vitro Cell Dev Biol Anim       Date:  1996-04       Impact factor: 2.416

2.  Retroviral mediated gene transfer in megakaryocytic cell lines.

Authors:  W R Kiffmeyer; P J Stambrook; M A Lieberman
Journal:  In Vitro Cell Dev Biol Anim       Date:  1994-11       Impact factor: 2.416

3.  Gastrointestinal epithelium is an early extrathymic site for increased prevalence of CD34(+) progenitor cells in contrast to the thymus during primary simian immunodeficiency virus infection.

Authors:  J J Mattapallil; Z Smit-McBride; S Dandekar
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

4.  Stem cell factor (SCF) synergizes with megakaryocyte colony stimulating activity in post-irradiated aplastic plasma in stimulating human megakaryocytopoiesis.

Authors:  V R Deutsch; A Eldor; T Olson; V Barak; M Pick; A Nagler
Journal:  Med Oncol       Date:  1996-03       Impact factor: 3.064

5.  Significance of stem cell factor and soluble KIT in patients with systemic lupus erythematosus.

Authors:  T Kitoh; H Ishikawa; S Sawada; K Koshino; Y Tokano; H Hashimoto; S Nakagawa
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

6.  Acute side effects of homologous interleukin-3 in rhesus monkeys.

Authors:  F C van Gils; A H Mulder; C van den Bos; H Burger; R W van Leen; G Wagemaker
Journal:  Am J Pathol       Date:  1993-12       Impact factor: 4.307

7.  Tumor necrosis factor-alpha inhibits stem cell factor-induced proliferation of human bone marrow progenitor cells in vitro. Role of p55 and p75 tumor necrosis factor receptors.

Authors:  L S Rusten; E B Smeland; F W Jacobsen; E Lien; W Lesslauer; H Loetscher; C M Dubois; S E Jacobsen
Journal:  J Clin Invest       Date:  1994-07       Impact factor: 14.808

8.  Thrombopoietin, the Mp1 ligand, is essential for full megakaryocyte development.

Authors:  K Kaushansky; V C Broudy; N Lin; M J Jorgensen; J McCarty; N Fox; D Zucker-Franklin; C Lofton-Day
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-11       Impact factor: 11.205

Review 9.  Development of platelet replacement therapy using human induced pluripotent stem cells.

Authors:  Sou Nakamura; Naoshi Sugimoto; Koji Eto
Journal:  Dev Growth Differ       Date:  2021-03-04       Impact factor: 2.053

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.